BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 128] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-hagen M, Neumann U, Schoening W. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary & Pancreatic Diseases International 2019;18:228-36. [DOI: 10.1016/j.hbpd.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
3 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
4 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
5 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
6 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B, Sørbye H, Aas E. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. Br J Surg 2019;106:132-41. [PMID: 30325494 DOI: 10.1002/bjs.10962] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Singal A, Welling TH, Marrero JA. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Review of Anticancer Therapy 2014;9:491-502. [DOI: 10.1586/era.09.5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Volk M, Marrero JA. Liver Transplantation for Hepatocellular Carcinoma: Who Benefits and Who Is Harmed? Gastroenterology 2008;134:1612-4. [DOI: 10.1053/j.gastro.2008.03.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
11 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Cillo U, Vitale A, Volk ML, Frigo AC, Feltracco P, Cattelan A, Brancaccio G, Feltrin G, Angeli P, Burra P, Lonardi S, Trapani S, Cardillo M. Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. Cancers (Basel) 2021;13:1416. [PMID: 33808790 DOI: 10.3390/cancers13061416] [Reference Citation Analysis]
13 González HD, Figueras J. Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. Clin Transl Oncol 2009;11:20-7. [DOI: 10.1007/s12094-009-0306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
15 Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:341-57. [PMID: 26558422 DOI: 10.1586/17474124.2016.1116381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Martins PN, Movahedi B, Bozorgzadeh A. Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases: A Paradigm Change? Ann Surg 2015;262:e12. [PMID: 24424153 DOI: 10.1097/SLA.0000000000000483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
17 Lai Q, Vitale A. Transplantation for hepatocellular cancer: pushing to the limits? Transl Gastroenterol Hepatol 2018;3:61. [PMID: 30363754 DOI: 10.21037/tgh.2018.09.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166-172. [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1] [Cited by in Crossref: 170] [Cited by in F6Publishing: 90] [Article Influence: 15.5] [Reference Citation Analysis]
19 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Quintini C, Hashimoto K, Uso TD, Miller C. Is there an advantage of living over deceased donation in liver transplantation? Transpl Int 2013;26:11-9. [PMID: 22937787 DOI: 10.1111/j.1432-2277.2012.01550.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
21 Vitale A, Volk ML, Gambato M, Zanus G, D'Amico F, Carraro A, Pauletto A, Bonsignore P, Scopelliti M, Polacco M, Russo F, Senzolo M, Burra P, Romano A, Angeli P, Cillo U. Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc 2010;42:1194-6. [PMID: 20534259 DOI: 10.1016/j.transproceed.2010.03.089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl 2020;26:1100-11. [PMID: 32531867 DOI: 10.1002/lt.25819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J;  iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64:1178-1188. [PMID: 27481548 DOI: 10.1002/hep.28744] [Cited by in Crossref: 132] [Cited by in F6Publishing: 112] [Article Influence: 22.0] [Reference Citation Analysis]
25 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
26 Levi DM, Tzakis AG, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo BL, Narayanan G, Garcia MT, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone AS. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg. 2010;210:727-734, 735-736. [PMID: 20421039 DOI: 10.1016/j.jamcollsurg.2010.01.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
27 Rich NE, Yopp AC, Singal AG. Medical Management of Hepatocellular Carcinoma. JOP 2017;13:356-64. [DOI: 10.1200/jop.2017.022996] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 4.4] [Reference Citation Analysis]
28 Lai Q, Melandro F, Rossi M, Ruberto F, Pugliese F, Mennini G. Role of perfusion machines in the setting of clinical liver transplantation: A qualitative systematic review. Clin Transplant 2018;32:e13310. [PMID: 29876967 DOI: 10.1111/ctr.13310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Washburn K, Black S. Winners and Losers: Allocating Scare Resources for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3113-4. [PMID: 28687874 DOI: 10.1245/s10434-017-5990-4] [Reference Citation Analysis]
30 Donat M, Alonso S, Pereira F, Ferrero E, Carrión L, Acin-Gándara D, Moreno E. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. Transplant Proc 2016;48:1968-77. [PMID: 27569930 DOI: 10.1016/j.transproceed.2016.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, Pawlik TM. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 2015;39:1474-1484. [PMID: 25665675 DOI: 10.1007/s00268-015-2987-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
32 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
33 Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma: . Current Opinion in Gastroenterology 2010;26:189-95. [DOI: 10.1097/mog.0b013e3283383ca5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
34 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
35 Bittermann T, Niu B, Hoteit MA, Goldberg D. Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach. Am J Transplant. 2014;14:79-87. [PMID: 24304509 DOI: 10.1111/ajt.12530] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
36 Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P;  Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43. [PMID: 19058754 DOI: 10.1016/s1470-2045(08)70284-5] [Cited by in Crossref: 1089] [Cited by in F6Publishing: 444] [Article Influence: 77.8] [Reference Citation Analysis]
37 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bhangui P, Saigal S, Gautam D, Piplani T, Choudhary N, Chaudhary R, Yadav S, Thiagarajan S, Rastogi A, Saraf N, Nundy S, Soin AS. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria. Liver Transpl 2021;27:209-21. [PMID: 33253492 DOI: 10.1002/lt.25956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT, Guo W, Liu J, Li JS, Jie-Yin, Zang YJ, Zhang ZT. miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2015;39:359-65. [PMID: 25543521 DOI: 10.1016/j.clinre.2014.09.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
40 Cucchetti A, Vitale A, Gaudio MD, Ravaioli M, Ercolani G, Cescon M, Zanello M, Morelli MC, Cillo U, Grazi GL, Pinna AD. Harm and Benefits of Primary Liver Resection and Salvage Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation 2010;10:619-27. [DOI: 10.1111/j.1600-6143.2009.02984.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
41 Commander SJ, Shaw B, Washburn L, Yoeli D, Rana A, Goss JA. A long-term experience with expansion of Milan criteria for liver transplant recipients. Clin Transplant 2018;32:e13254. [DOI: 10.1111/ctr.13254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66:1910-1919. [PMID: 28653750 DOI: 10.1002/hep.29342] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
43 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Lee KW, Kim SH, Yoon KC, Lee JM, Cho JH, Hong SK, Yi NJ, Han SS, Park SJ, Suh KS. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. J Clin Med 2020;9:E3264. [PMID: 33053849 DOI: 10.3390/jcm9103264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Cucchetti A, Cescon M, Bertuzzo V, Bigonzi E, Ercolani G, Morelli MC, Ravaioli M, Pinna AD. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? Am J Transplant 2011;11:1696-704. [PMID: 21668632 DOI: 10.1111/j.1600-6143.2011.03570.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 146] [Article Influence: 24.7] [Reference Citation Analysis]
47 Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832-838. [PMID: 19152426 DOI: 10.1002/hep.22693] [Cited by in Crossref: 240] [Cited by in F6Publishing: 229] [Article Influence: 18.5] [Reference Citation Analysis]
48 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
49 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(1170175-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Kim PTW, Onaca N, Chinnakotla S, Davis GL, Jennings LW, Mckenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013;27:311-8. [DOI: 10.1111/ctr.12089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
51 Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17 Suppl 2:S81-S89. [PMID: 21748847 DOI: 10.1002/lt.22380] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
52 Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastro 2017;15:296-304. [DOI: 10.1007/s11938-017-0133-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
53 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
54 Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, Gao F, Tu Z, Wang W, Zhang M, Shen Y, Xie H, Jiang W, Wang H, Zheng S. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65:1035-1041. [PMID: 25804634 DOI: 10.1136/gutjnl-2014-308513] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 11.9] [Reference Citation Analysis]
55 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
56 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
57 Kulik L, Salem R. Downstaging: Looking for answers, generating more questions? Liver Transpl 2015;21:1117-9. [PMID: 26147566 DOI: 10.1002/lt.24209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
59 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
60 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
61 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
62 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 9.4] [Reference Citation Analysis]
63 Lünse S, Heidecke C, Partecke LI; Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General, Visceral and Thoracic Surgery, Helios Klinikum Schleswig, Schleswig, Germany. Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 111-25. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
65 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
66 Briceño J, Ciria R, de la Mata M. Donor-recipient matching: Myths and realities. Journal of Hepatology 2013;58:811-20. [DOI: 10.1016/j.jhep.2012.10.020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
67 Pelletier SJ, Fu S, Thyagarajan V, Romero-marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data: Liver Transplantation for HCC. Liver Transpl 2009;15:859-68. [DOI: 10.1002/lt.21778] [Cited by in Crossref: 112] [Cited by in F6Publishing: 100] [Article Influence: 8.6] [Reference Citation Analysis]
68 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
69 Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:34-41. [PMID: 21115579 DOI: 10.1634/theoncologist.2010-s4-34] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
70 Degroote H, Callebout E, Iesari S, Dekervel J, Schreiber J, Pirenne J, Verslype C, Ysebaert D, Michielsen P, Lucidi V, Moreno C, Detry O, Delwaide J, Troisi RI, Lerut JP, Van Vlierberghe H; Be-LIAC. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2020;33:231-8. [PMID: 31630912 DOI: 10.1016/j.suronc.2019.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
71 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
72 Chaib E, Amaku M, Coutinho FA, Lopez LF, Burattini MN, D'Albuquerque LA, Massad E. A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma. Theor Biol Med Model 2013;10:60. [PMID: 24139285 DOI: 10.1186/1742-4682-10-60] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Cucchetti A, Cescon M, Trevisani F, Morelli MC, Ercolani G, Pellegrini S, Erroi V, Bigonzi E, Pinna AD. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? Dig Liver Dis. 2012;44:523-529. [PMID: 22387286 DOI: 10.1016/j.dld.2012.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
74 Yang PC, Akamatsu N, Hasegawa K, Kokudo N. Twenty years of Milan criteria: how far do we go. Hepatobiliary Surg Nutr 2016;5:488-91. [PMID: 28124004 DOI: 10.21037/hbsn.2016.12.01] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. Hepatobiliary Surg Nutr 2017;6:280-3. [PMID: 28848755 DOI: 10.21037/hbsn.2017.03.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Akoad ME, Pomfret EA. Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:381-99. [DOI: 10.1016/j.cld.2015.01.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
77 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 11.0] [Reference Citation Analysis]
78 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
79 Toniutto P, Fumolo E, Fornasiere E, Bitetto D. Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med 2021;10:3932. [PMID: 34501381 DOI: 10.3390/jcm10173932] [Reference Citation Analysis]
80 Lai Q, Rossi M. Survivals after liver transplantation for hepatocellular carcinoma: Granular data for a better allocation process? Hepatobiliary Pancreat Dis Int 2018;17:374-5. [PMID: 29866607 DOI: 10.1016/j.hbpd.2018.04.009] [Reference Citation Analysis]
81 Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando). 2010;24:11-17. [PMID: 19942101 DOI: 10.1016/j.trre.2009.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
82 Guiteau JJ, Cotton RT, Washburn WK, Harper A, O’Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant. 2010;10:2092-2098. [PMID: 20883543 DOI: 10.1111/j.1600-6143.2010.03222.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
83 Xu M, Doyle MM, Banan B, Vachharajani N, Wang X, Saad N, Fowler K, Brunt EM, Lin Y, Chapman WC. Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Am Coll Surg. 2017;225:28-40. [PMID: 28400300 DOI: 10.1016/j.jamcollsurg.2017.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
84 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 177] [Article Influence: 31.0] [Reference Citation Analysis]
85 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
86 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Schmelzle M, Krenzien F, Schöning W, Pratschke J. [Treatment of hepatocellular carcinoma in the cirrhotic and non-cirrhotic liver]. Chirurg 2018;89:851-7. [PMID: 30109374 DOI: 10.1007/s00104-018-0690-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
88 Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 431-47. [DOI: 10.1007/978-1-59745-565-7_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
90 Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:498-502. [PMID: 28124007 DOI: 10.21037/hbsn.2016.12.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Kensinger CD, Dageforde LA, Moore DE. Can donors with high donor risk indices be used cost-effectively in liver transplantation in US Transplant Centers? Transpl Int 2013;26:1063-9. [DOI: 10.1111/tri.12184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
92 Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology 2014;146:1256-65.e1. [PMID: 24412528 DOI: 10.1053/j.gastro.2014.01.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
93 Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanus G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010;42:642-9. [PMID: 20381438 DOI: 10.1016/j.dld.2010.02.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
94 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 239] [Article Influence: 22.5] [Reference Citation Analysis]
95 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
96 Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. J Dig Dis. 2013;14:552-558. [PMID: 23782458 DOI: 10.1111/1751-2980.12083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
97 Vitale A, Volk M, Cillo U. Transplant benefit for patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(48): 9183-9188 [PMID: 24409046 DOI: 10.3748/wjg.v19.i48.9183] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
98 Dutkowski P, Schlegel A, Slankamenac K, Oberkofler CE, Adam R, Burroughs AK, Schadde E, Müllhaupt B, Clavien PA. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256:861-868; discussion 868-869. [PMID: 23095632 DOI: 10.1097/sla.0b013e318272dea2] [Cited by in Crossref: 91] [Cited by in F6Publishing: 28] [Article Influence: 10.1] [Reference Citation Analysis]
99 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Gilbo N, Jochmans I, Sainz-Barriga M, Nevens F, van der Merwe S, Laleman W, Verslype C, Cassiman D, Verbeke L, van Malenstein H, Roskams T, Pirenne J, Monbaliu D. Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully Selected. Transplant Direct 2019;5:e342. [PMID: 30993187 DOI: 10.1097/TXD.0000000000000883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
101 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
102 Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010;16:925-929. [PMID: 20658555 DOI: 10.1002/lt.22103] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
103 Perkins JD, Halldorson JB, Bakthavatsalam R, Fix OK, Carithers RL Jr, Reyes JD. Should liver transplantation in patients with model for end-stage liver disease scores <or= 14 be avoided? A decision analysis approach. Liver Transpl. 2009;15:242-254. [PMID: 19177441 DOI: 10.1002/lt.21703] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
104 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018; 24(32): 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
105 Cillo U, Vitale A, Dupuis D, Corso S, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Zanus G. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. PLoS One 2013;8:e57249. [PMID: 23437351 DOI: 10.1371/journal.pone.0057249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
106 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
107 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
108 Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol. 2012;56:618-625. [PMID: 22027581 DOI: 10.1016/j.jhep.2011.08.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
109 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
110 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
111 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
112 Ma KW, Cheung TT. When to consider liver transplantation in hepatocellular carcinoma patients? Hepat Oncol. 2017;4:15-24. [PMID: 30191050 DOI: 10.2217/hep-2016-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
113 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
114 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
116 Yopp AC, Marrero JA, Singal AG. Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope? Ann Surg Oncol 2017;24:1758-60. [DOI: 10.1245/s10434-017-5802-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
117 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
118 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
119 Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010;51:165-73. [DOI: 10.1002/hep.23260] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
120 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
121 Vitale A, D’Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, Neri D, Carraro A, D’Amico FE, Burra P. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17:2290-2302. [PMID: 20217249 DOI: 10.1245/s10434-010-0993-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
122 Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. Transpl Int 2015;28:1055-65. [PMID: 25865602 DOI: 10.1111/tri.12591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
123 Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl. 2011;17 Suppl 2:S133-S138. [PMID: 21634006 DOI: 10.1002/lt.22348] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
124 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
125 Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, Treanor D, Morris-Stiff G, Jones RL, Prasad KR. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013;15:418-427. [PMID: 23458127 DOI: 10.1111/hpb.12008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
126 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A;  OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9] [Cited by in Crossref: 600] [Cited by in F6Publishing: 235] [Article Influence: 54.5] [Reference Citation Analysis]
127 Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts. Transplantation. 2013;96:995-999. [PMID: 23924774 DOI: 10.1097/tp.0b013e3182a339a7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
128 Livraghi T, Brambilla G, Carnaghi C, Tommasini MA, Torzilli G. Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol. 2010;102:868-876. [PMID: 20886553 DOI: 10.1002/jso.21733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
129 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
130 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
131 Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology 2021:S0016-5085(21)03284-4. [PMID: 34331914 DOI: 10.1053/j.gastro.2021.07.033] [Reference Citation Analysis]
132 Guo WH, Zhang JX. Current status on comprehensive treatment of hepatoma. Shijie Huaren Xiaohua Zazhi 2008; 16(20): 2199-2203 [DOI: 10.11569/wcjd.v16.i20.2199] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
133 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Xu X, Guo HJ, Xie HY, Li J, Zhuang RZ, Ling Q, Zhou L, Wei XY, Liu ZK, Ding SM, Chen KJ, Xu ZY, Zheng SS. ZIP4, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation. Int J Biol Sci. 2014;10:245-256. [PMID: 24643086 DOI: 10.7150/ijbs.7401] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]